Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide
Status:
Completed
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the bioequivalence (BE) of new coated Cesol tablet
(Test) versus Biltricide tablets (Comparator) in healthy male participants. Praziquantel
(rac-PZQ) is the active ingredient for Cesol and Biltricide tablets.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany